ExLibris header image
SFX Logo
Title: The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs
Source:

Proceedings of the National Academy of Sciences of the United States of America [0027-8424] Kavanagh, K L yr:2006


Collapse list of basic services Basic
Full text
Full text available via PubMed Central
GO
Document delivery
Request document via Library/Bibliothek GO
Users interested in this article also expressed an interest in the following:
1. Rondeau, M. "Structural Basis for the Exceptional in vivo Efficacy of Bisphosphonate Drugs." ChemMedChem 1.2 (2006): 267-273. Link to Full Text for this item Link to SFX for this item
2. Roelofs, Anke J. "Molecular mechanisms of action of bisphosphonates: current status." Clinical cancer research 12.20 (2006): 6222-30. Link to SFX for this item
3. Drake, Matthew T T. "Bisphosphonates: mechanism of action and role in clinical practice." Mayo Clinic proceedings 83.9 (2008): 1032-45. Link to SFX for this item
4. Zheng, Zhong-Liang, Z. "Probing the importance of hydrogen bonds in the active site of the subtilisin nattokinase by site-directed mutagenesis and molecular dynamics simulation." The Biochemical journal 395.Part 3 (2006): 509-515. Link to Full Text for this item Link to SFX for this item
5. Wally, J. "The crystal structure of iron-free human serum transferrin provides insight into inter-lobe communication and receptor binding." The Journal of biological chemistry 281.34 (2006): 24934-24944. Link to Full Text for this item Link to SFX for this item
6. Coxon, Fraser P P. "Recent advances in understanding the mechanism of action of bisphosphonates." Current opinion in pharmacology 6.3 (2006): 307-12. Link to SFX for this item
7. Abrahamsen, STYPEPERIODICALDOCID000002038659371 o. "Adverse Effects of Bisphosphonates." Calcified Tissue International 86.6 (2010): 421-435. Link to SFX for this item
8. Papaioannou, A. "2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary." Canadian Medical Association. Journal; CMAJ 182.17 (2010): 1864-73. Link to Full Text for this item Link to SFX for this item
9. Ory, B. "Farnesyl diphosphate synthase is involved in the resistance to zoledronic acid of osteosarcoma cells." Journal of Cellular and Molecular Medicine 12.3 (2008): 928-941. Link to Full Text for this item Link to SFX for this item
10. Lill, Markus A A. "Prediction of small-molecule binding to cytochrome P450 3A4: Flexible docking combined with multidimensional QSAR." ChemMedChem 1.1 (2006): 73-81. Link to Full Text for this item Link to SFX for this item
11. Cheung, Moira S S. "Osteogenesis Imperfecta : Update on presentation and management." Reviews in endocrine & metabolic disorders 9.2 (2008): 153-160. Link to SFX for this item
12. Thulasiram, Hirekodathakallu V. "Farnesyl diphosphate synthase: The art of compromise between substrate selectivity and stereoselectivity." Journal of the American Chemical Society 128.49 (2006): 15819-15823. Link to Full Text for this item Link to SFX for this item
13. Russell, R Graham G G. "Bisphosphonates: from bench to bedside." Annals of the New York Academy of Sciences 1068.1 (2006): 367-401. Link to Full Text for this item Link to SFX for this item
14. Lambrinoudaki, I. "Bisphosphonates." Annals of the New York Academy of Sciences 1092.1 (2007): 397-402. Link to Full Text for this item Link to SFX for this item
15. Chou, T.C. C. "Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors." Advances in enzyme regulation 22.C (1984): 27-55. Link to Full Text for this item Link to SFX for this item
16. Rogers, M J J. "Overview of bisphosphonates." Cancer 80.8 Suppl (1997): 1652-60. Link to Full Text for this item Link to SFX for this item
17. Neer, R M M. "Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis." New England Journal of Medicine, The 344.19 (2001): 1434-41. Link to SFX for this item
18. Silverman, E. "Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment." Journal of oral and maxillofacial surgery 65.12 (2008): 1320-1. Link to SFX for this item
19. TSUNOO, H. "PLACENTAL TRANSFERRIN RECEPTOR - EVALUATION OF THE PRESENCE OF ENDOGENOUS LIGAND ON SPECIFIC BINDING." The Journal of biological chemistry 258.7 (1983): 4118-4122. Link to SFX for this item
20. Black, Dennis M. "Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis." The New England journal of medicine 356.18 (2007): 1809-22. Link to SFX for this item
View More...
View Less...
Select All Clear All

Expand list of advanced services Advanced
A service provided by the Library of the Wissenschaftspark Albert Einstein, Potsdam, Germany.
© 2005 SFX by Ex Libris Inc.